Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of therapy in adult mature B-cell acute lymphoblastic leukemia and Burkitt's lymphoma with rituximab
2005-001067-64Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in acute lymphoblastic leukemia (ALL) and Burkitt lymphoma (BL), sponsored by Fundación PETHEMA. Primary endpoints: Complete remission rate, Disease-free survival (DFS) and 2 more. Started May 2006; status: active.
02
Drugs
rituximab
03
Conditions
acute lymphoblastic leukemia (ALL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2005-001067-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001067-64.